Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis.

Cai X, Pacheco-Rodriguez G, Fan QY, Haughey M, Samsel L, El-Chemaly S, Wu HP, McCoy JP, Steagall WK, Lin JP, Darling TN, Moss J.

Am J Respir Crit Care Med. 2010 Dec 1;182(11):1410-8. doi: 10.1164/rccm.201003-0489OC. Epub 2010 Jul 16.

2.

Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis.

Crooks DM, Pacheco-Rodriguez G, DeCastro RM, McCoy JP Jr, Wang JA, Kumaki F, Darling T, Moss J.

Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17462-7. Epub 2004 Dec 6.

3.

Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis.

Sato T, Seyama K, Fujii H, Maruyama H, Setoguchi Y, Iwakami S, Fukuchi Y, Hino O.

J Hum Genet. 2002;47(1):20-8.

PMID:
11829138
4.

Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.

Cai X, Pacheco-Rodriguez G, Haughey M, Samsel L, Xu S, Wu HP, McCoy JP, Stylianou M, Darling TN, Moss J.

Chest. 2014 Jan;145(1):108-12. doi: 10.1378/chest.13-1071.

5.

TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis.

Pacheco-Rodriguez G, Steagall WK, Crooks DM, Stevens LA, Hashimoto H, Li S, Wang JA, Darling TN, Moss J.

Cancer Res. 2007 Nov 1;67(21):10573-81.

6.
7.

Detection of low-prevalence somatic TSC2 mutations in sporadic pulmonary lymphangioleiomyomatosis tissues by deep sequencing.

Fujita A, Ando K, Kobayashi E, Mitani K, Okudera K, Nakashima M, Miyatake S, Tsurusaki Y, Saitsu H, Seyama K, Miyake N, Matsumoto N.

Hum Genet. 2016 Jan;135(1):61-8. doi: 10.1007/s00439-015-1611-0. Epub 2015 Nov 12.

PMID:
26563443
8.

Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis.

Yu J, Astrinidis A, Henske EP.

Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1537-40.

PMID:
11704609
9.

Clinical and molecular insights into lymphangioleiomyomatosis.

Steagall WK, Taveira-DaSilva AM, Moss J.

Sarcoidosis Vasc Diffuse Lung Dis. 2005 Dec;22 Suppl 1:S49-66. Review.

PMID:
16457017
10.

Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.

Li C, Zhang E, Sun Y, Lee PS, Zhan Y, Guo Y, Osorio JC, Rosas IO, Xu KF, Kwiatkowski DJ, Yu JJ.

PLoS One. 2014 Oct 27;9(10):e104809. doi: 10.1371/journal.pone.0104809. eCollection 2014 Oct 27.

11.

Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.

Steagall WK, Pacheco-Rodriguez G, Glasgow CG, Ikeda Y, Lin JP, Zheng G, Moss J.

Am J Pathol. 2013 Sep;183(3):938-50. doi: 10.1016/j.ajpath.2013.05.024. Epub 2013 Jul 16.

12.

Multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis with a TSC2 gene.

Maruyama H, Seyama K, Sobajima J, Kitamura K, Sobajima T, Fukuda T, Hamada K, Tsutsumi M, Hino O, Konishi Y.

Mod Pathol. 2001 Jun;14(6):609-14.

13.

Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene.

Pacheco-Rodriguez G, Kumaki F, Steagall WK, Zhang Y, Ikeda Y, Lin JP, Billings EM, Moss J.

J Immunol. 2009 Feb 1;182(3):1270-7.

14.

Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis.

Astrinidis A, Khare L, Carsillo T, Smolarek T, Au KS, Northrup H, Henske EP.

J Med Genet. 2000 Jan;37(1):55-7.

15.

Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM.

Lesma E, Grande V, Ancona S, Carelli S, Di Giulio AM, Gorio A.

PLoS One. 2008;3(10):e3558. doi: 10.1371/journal.pone.0003558. Epub 2008 Oct 29.

16.

TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex.

Muzykewicz DA, Sharma A, Muse V, Numis AL, Rajagopal J, Thiele EA.

J Med Genet. 2009 Jul;46(7):465-8. doi: 10.1136/jmg.2008.065342. Epub 2009 May 5.

PMID:
19419980
17.

TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival.

Lesma E, Ancona S, Sirchia SM, Orpianesi E, Grande V, Colapietro P, Chiaramonte E, Di Giulio AM, Gorio A.

J Cell Mol Med. 2014 May;18(5):766-79. doi: 10.1111/jcmm.12237. Epub 2014 Mar 7.

18.

Biallelic TSC gene inactivation in tuberous sclerosis complex.

Crino PB, Aronica E, Baltuch G, Nathanson KL.

Neurology. 2010 May 25;74(21):1716-23. doi: 10.1212/WNL.0b013e3181e04325.

19.

The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis.

Strizheva GD, Carsillo T, Kruger WD, Sullivan EJ, Ryu JH, Henske EP.

Am J Respir Crit Care Med. 2001 Jan;163(1):253-8.

PMID:
11208653
20.

Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.

Makovski V, Haklai R, Kloog Y.

Int J Cancer. 2012 Mar 15;130(6):1420-9. doi: 10.1002/ijc.26139. Epub 2011 Aug 1.

Supplemental Content

Support Center